WHAT THE STUDY ADDS
Heart failure, HF, coronary artery disease, left ventricular systolic dysfunction
HEART FAILURE, LEFT VENTRICULAR SYSTOLIC DYSFUNCTION, CORONARY ARTERY DISEASE
This study evaluates the economic implications associated with PCI in ischemic left ventricular systolic dysfunction patients, filling a crucial knowledge gap.Results indicate that although PCI provides similar health benefits, it comes at a higher cost when compared with optimal medical therapy alone.Most health resource utilization occurred in the first 6 months post-randomization, related to the PCI procedures.Study findings indicate that routine PCI as a treatment strategy for ischemic left ventricular systolic dysfunction is not cost-effective, which has implications for health care resource allocation.
Heart failure (HF) is an increasing worldwide health problem, with coronary artery disease being the most common cause.In the REVIVED trial, it was hypothesized that revascularization with PCI in addition to optimal MT (OMT) compared with OMT alone could improve event-free survival in patients with severe ischemic left ventricular systolic dysfunction (ILVD).The aim of our current analysis was to assess the cost-effectiveness of PCI for patients with severe stable ILVD by using patient-level resource use and patient-reported outcome data collected in the REVIVED trial.